Relationship between Motor and Nonmotor Symptoms and Quality of Life in Patients with Parkinson’s Disease
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
4.1. Implications for Clinical Practice
4.2. Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ministerio de Sanidad. Patrones de Mortalidad en España, 2017; Ministerio de Sanidad: Madrid, Spain, 2020. Available online: http://www.ine.es/infoine (accessed on 10 July 2020).
- Monchi, O.; Hanganu, A.; Bellec, P. Markers of cognitive decline in PD: The case for heterogeneity. Parkinsonism Relat. Disord. 2016, 24, 8–14. [Google Scholar] [CrossRef]
- Von Campenhausen, S.; Bornschein, B.; Wick, R.; Bötzel, K.; Sampaio, C.; Poewe, W.; Oertel, W.; Siebert, U.; Berger, K.; Dodel, R. Prevalence and incidence of Parkinson’s disease in Europe. Eur. Neuropsychopharmacol. 2005, 15, 473–490. [Google Scholar] [CrossRef] [PubMed]
- López del Val, L. Enfermedad de Parkinson. In Parkinson y Discinesias; López del Val, L.J., Linazasoro Cristobal, G., Eds.; Abordaje Diagnóstico y Terapéutico; Médica Panamericana, S.A.: Madrid, Spain, 2012; pp. 215–268. [Google Scholar]
- Tu, X.-J.; Hwang, W.-J.; Ma, H.-I.; Chang, L.H.; Hsu, S.-P. Determinants of generic and specific health-related quality of life in patients with Parkinson’s disease. PLoS ONE 2017, 12, e0178896. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- García-Ramos, R.; López Valdés, E.; Ballesteros, L.; de Jesús, S.; Mir, P. Informe de la Fundación del cerebro sobre el impacto social de la Enfermedad de Parkinson en España. Neurología 2016, 31, 401–413. [Google Scholar] [CrossRef] [PubMed]
- Benito-León, J. Epidemiología de la enfermedad de Parkinson en España y su contextualización mundial. Rev. Neurol. 2018, 66, 125–134. [Google Scholar] [CrossRef] [PubMed]
- Duncan, G.W.; Khoo, T.K.; Yarnall, A.J.; O’Brien, J.T.; Coleman, S.Y.; Brooks, D.J.; Barker, R.A.; Burn, D.J. Health-Related Quality of Life in Early Parkinson’s Disease: The Impact of Nonmotor Symptoms. Mov. Disord. 2014, 29, 195–202. [Google Scholar] [CrossRef] [PubMed]
- Gómez-Esteban, J.; Tijero, B.; Somme, J.; Ciordia, R.; Berganzo, K.; Rouco, I.; Bustos, J.L.; Valle, M.A.; Lezcano, E.; Zarranz, J.J. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J. Neurol. 2011, 258, 494–499. [Google Scholar] [CrossRef]
- Schiavolin, S.; Raggi, A.; Quintas, R.; Cerniauskaite, M.; Giovannetti, A.M.; Covelli, V.; Romitoet, L.; Elia, A.E.; Carella, F.; Soliveri, P.; et al. Psychosocial difficulties in patients with Parkinson’s disease. Int. J. Rehabil. Res. 2017, 40, 112–118. [Google Scholar] [CrossRef]
- Benito-León, J.; Cubo, E.; Coronell, C.; ANIMO Study Group. Impact of Apathy on Health-Related Quality of Life in Recently Diagnosed Parkinson’s Disease: The ANIMO Study. Mov. Disord. 2012, 27, 211–217. [Google Scholar] [CrossRef]
- Yamanishi, T.; Tachibana, H.; Oguru, M.; Matsui, K.; Toda, K.; Okuda, B.; Oka, N. Anxiety and Depression in Patients with Parkinson’s Disease. Intern Med. 2013, 52, 539–545. [Google Scholar] [CrossRef] [Green Version]
- Hoehn, M.M.; Yahr, M.D. Parkinsonism: Onset, progression, and mortality. Neurology 1967, 17, 427–442. [Google Scholar] [CrossRef] [Green Version]
- Alonso Cánovas, A.; Luquin Piudo, R.; García Ruiz-Espiga, P.; Burguera, J.; Campos Arillo, V.; Castro, A.; Linazasoro, G.; Lopez del Val, J.; Vela, L.; Martínez Castrillo, J.C. Agonistas dopaminérgicos en la enfermedad de Parkinson. Neurología 2014, 29, 230–241. [Google Scholar] [CrossRef] [PubMed]
- Ruiz-García, M.; Gómez-Hontanilla, M.; Ruiz-García, A.; Ruiz-García, J.; Ruiz-García, A.; Herráez-Izquierdo, V. Calidad de vida de los enfermos de Parkinson tras tratamiento quirúrgico. Rev. Cient. Soc. Esp. Enferm. Neurol. 2011, 3, 10–15. [Google Scholar]
- Balestrino, R.; Martinez-Martin, P. Reprint of Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson’s disease. J. Neurol. Sci. 2017, 374, 3–8. [Google Scholar] [CrossRef] [PubMed]
- Rahman, S.; Hall, J.; Griffin, A.; Jahanshahi, M. Quality of life in Parkinson’s disease: The relative importance of the symptoms. Mov. Disord. 2008, 23, 1428–1434. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Martín, P.; Payo, B.F.; The Grupo Centro for Study of Movement Disorders. Quality of life in Parkinson’s disease: Validation study of the PDQ-39 Spanish version. J. Neurol. 1998, 245 (Suppl. S1), S34–S38. [Google Scholar] [CrossRef] [PubMed]
- Real Decreto 1971/1999 de 23 de Diciembre Sobre Procedimiento Para el Reconocimiento, Declaración y Calificación del Grado de Discapacidad. Available online: https://www.boe.es/eli/es/rd/1999/12/23/1971/con (accessed on 10 December 2020).
- Hernández Lalinde, J.; Espinosa Castro, J.; Peñaloza Tarazona, M.; Rodriguez, J.; Chacón Rangel, J.; Toloza Sierra, C.; Arenas-Torrado, M.K.; Carrillo-Sierra, S.M.; Bermudez-Pirela, V.J. On the proper use of the Pearson correlation coefficient: Definitions, properties and assumptions. AVFT Arch. Venez. Farmacol. Ter. 2018, 37, 587–595. [Google Scholar]
- Martínez-Fernández, R.; Gasca-salas, C.; Sánchez-Ferro, A.; Obeso, J. Actualización de la Enfermedad de Parkinson. Parkinson’s disease: A review . Rev. Med. Clin. Condes 2016, 27, 363–379. [Google Scholar] [CrossRef] [Green Version]
- Erro, R.; Picillo, M.; Vitale, C.; Amboni, M.; Moccia, M.; Santangelo, G.; Pellecchia, M.T.; Barone, P. The non-motor side of the honeymoon period of Parkinson’s disease and its relationship with quality of life: A 4-year longitudinal study. Eur. J. Neurol. 2016, 23, 1673–1679. [Google Scholar] [CrossRef]
- Candel-Parra, E.; Córcoles-Jiménez, P.; Delicado-USeros, V.; Hernández-Martínez, A.; Molina-Alarcón, M. Evolution of Quality of life in persons with Parkinson’s disease: A prospective cohort study. J. Clin. Med. 2021, 10, 1824. [Google Scholar] [CrossRef]
- Hassan, A.; Wu, S.S.; Schmidt, P.; Malaty, I.A.; Dai, Y.F.; Miyasaki, J.M.; Okun, M.S. What are the issues facing Parkinson’s disease patients at ten years of disease and beyond? Data from the NPF-QII study. Park. Relat. Disord. 2012, 18, S10–S14. [Google Scholar] [CrossRef] [PubMed]
- Prakash, K.; Nadkarnid, N.; Lye, W.; Yong, M.H.; Tan, E.K. The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: A longitudinal study. Eur. J. Neurol. 2016, 23, 854–860. [Google Scholar] [CrossRef] [PubMed]
- D’Iorio, A.; Vitale, C.; Piscopo, F.; Chiara Baiano, C.; Falanga, A.; Longo, K.; Amboni, M.; Barone, P.; Santangelo, G. Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson’s disease. Parkinsonism Relat. Disord. 2017, 43, 114–117. [Google Scholar] [CrossRef]
- Conran, J.; Jonsson-Lecaprea, J.; Wicksell, R.; Svenningssond, P.; Franzéna, E. Pain in persons with mild-moderate Parkinson’s disease: A cross-sectional study of pain severity and associated factors. Int. J. Rehabil. Res. 2019, 42, 371–376. [Google Scholar]
- Sheard, J.; Ash, S.; Mellick, G.; Silburn, P.; Kerr, G. Improved nutritional status is related to improved quality of life in Parkinson’s disease. BMC Neurol. 2014, 14, 212. [Google Scholar] [CrossRef] [Green Version]
- Navarta-Sánchez, M.; Senosiain-García, J.; Riverol, M.; Ursúa-Sesma, M.; Díazde Cerio-Ayesa, S.; Anaut-Bravo, S.; Civera, N.C.; Portillo, M.C. Factors influencing psychosocial adjustment and quality of life in Parkinson patients and informal caregivers. Qual Life Res. 2016, 25, 1959–1968. [Google Scholar] [CrossRef] [Green Version]
- Martinez-Martin, P. What is quality of life and how do we measure it? Relevance to Parkinson’s disease and movement disorders. Mov. Disord. 2017, 32, 382–392. [Google Scholar] [CrossRef]
- Schuepbach, W.; Rau, J.; Knudsen, K.; Volkmann, J.; Krack, P.; Timmermann, L.; Hälbig, T.; Hesekamp, H.; Navarro, S.; Meier, N.; et al. Neurostimulation for Parkinson’s Disease with Early Motor Complications. N. Engl. J. Med. 2013, 368, 610–622. [Google Scholar] [CrossRef] [Green Version]
Variable | % (n) N = 155 |
---|---|
Mean age (SD) 95% CI | 69.51 (8.63) 68.14–70.88 |
Sex | |
Male | 59.4 (92) |
Female | 40.6 (63) |
Living situation | |
In a family | 85.8 (133) |
Lives alone | 9.7 (15) |
In a residence | 4.5 (7) |
Civil status | |
Married | 75.5 (117) |
Widowed | 16.1 (25) |
Divorced | 1.9 (3) |
Employment situation | |
Retired | 73.5 (114) |
Housework | 19.4 (30) |
Actively employed | 5.2 (8) |
Education | |
No education | 0.6 (1) |
Primary level | 82.6 (128) |
Secondary level | 12.3 (19) |
University level | 4.5 (7) |
HY stage | |
Stage 1, 2 | 67.1 (104) |
Stage 3, 4, 5 | 32.9 (51) |
Surgery for neurostimulation | |
Yes | 20.6 (32) |
No | 79.4 (123) |
Medicines consumption | |
≥4 medicines | 41.3 (64) |
<4 medicines | 58.7 (91) |
Score Mean (SD) 95% CI | HY Stage | Mean (SD) | Mean Difference | 95% CI | p | |
---|---|---|---|---|---|---|
Total PDQ-39 SI | 27.47 (16.14) 24.91–30.03 | Stage 1, 2 | 20.17 (11.97) | −22.2 | −26.3, −18.03 | 0.001 * |
Stage 3, 4, 5 | 42.37 (13.06) | |||||
Total mobility | 36.08 (30.18) 29.99–39.97 | Stage 1, 2 | 21.92 (20.65) | −43.02 | −50.6, −35.45 | 0.001 * |
Stage 3, 4, 5 | 64.95 (25.69) | |||||
Total ADL | 32.04 (27.71) 25.82–34.76 | Stage 1, 2 | 19.79 (19.29) | −37.23 | −44.5 −29.96 | 0.001 * |
Stage 3, 4, 5 | 57.02 (25.48) | |||||
Total emotional well-being | 36.23 (24.03) 32.23–40.05 | Stage 1, 2 | 30.32 (23.60) | −17.95 | −25.5, −10.33 | 0.001 * |
Stage 3, 4, 5 | 48.28 (20.27) | |||||
Total stigma | 19.23 (24.55) 15.33–23.13 | Stage 1, 2 | 13.64 (20.13) | −16.99 | −24.8, −9.13 | 0.001 * |
Stage 3, 4, 5 | 30.63 (28.70) | |||||
Total social support | 18.49 (18.54) 15.55–21.43 | Stage 1, 2 | 16.74 (16.92) | −5.31 | −11.5, −0.91 | 0.094 |
Stage 3, 4, 5 | 22.05 (21.2) | |||||
Total cognitive status | 29.27 (20.95) 25.94–32.59 | Stage 1, 2 | 22.71 (18.47) | −19.93 | −26.2, −13.58 | 0.001 * |
Stage 3, 4, 5 | 42.64 (19.43) | |||||
Total communication | 16.07 (19.99) 12.9–19.24 | Stage 1, 2 | 9.21 (13.97) | −20.85 | −26.7, −14.95 | 0.001 * |
Stage 3, 4, 5 | 30.06 (23.03) | |||||
Total pain | 32.36 (23.02) 28.71–36.01 | Stage 1, 2 | 27.00 (21.42) | −16.29 | −23.6, −8.78 | 0.001 * |
Stage 3, 4, 5 | 43.3 (22.48) |
N = 155 | No. of MS | No. of NMS | No. of MS + NMS | |||
---|---|---|---|---|---|---|
Pearson’s Correlation (r) | p | Pearson’s Correlation (r) | p | Pearson’s Correlation (r) | p | |
PDQ-39 SI | 0.705 | 0.001 * | 0.732 | 0.001 * | 0.732 | 0.001 * |
Mobility | 0.534 | 0.001 * | 0.528 | 0.001 * | 0.603 | 0.001 * |
ADLs | 0.531 | 0.001 * | 0.473 | 0.001 * | 0.562 | 0.001 * |
Emotional well-being | 0.352 | 0.001 * | 0.567 | 0.001 * | 0.557 | 0.001 * |
Stigma | 0.177 | 0.028 * | 0.319 | 0.001 * | 0.305 | 0.001 * |
Social support | 0.131 | 0.105 | 0.187 | 0.020 * | 0.189 | 0.018 * |
Cognitive state | 0.404 | 0.001 * | 0.565 | 0.001 * | 0.577 | 0.001 * |
Communication | 0.343 | 0.001 * | 0.354 | 0.001 * | 0.398 | 0.001 * |
Pain | 0.401 | 0.001 * | 0.543 | 0.001 * | 0.559 | 0.001 * |
Motor Symptoms | n (%) | PDQ-39 SI Score Mean (SD) | Mean Difference | 95% CI | p | |
---|---|---|---|---|---|---|
Slowness of movement | Yes | 137 (88.4) | 29.44 (15.65) | 16.92 | 9.37, 24.48 | 0.001 * |
No | 18 (11.6) | 12.51 (11.55) | ||||
Postural instability | Yes | 96 (61.9) | 32.8 (15.47) | 14.00 | 9.2, 18.8 | 0.001 * |
No | 59 (38.1) | 18.8 (13.3) | ||||
Difficulty turning | Yes | 71 (45.8) | 35.8 (13.35) | 15.37 | 10.83, 19.91 | 0.001 * |
No | 84 (54.2) | 20.43 (14.95) | ||||
Tremor | Yes | 81 (52.3) | 27.96 (16.32) | 1.01 | −4.12, 6.16 | 0.697 |
No | 74 (47.7) | 26.94 (16.04) | ||||
Dyskinesias | Yes | 45 (29) | 34.5 (15.5) | 9.71 | 4.26, 15.15 | 0.001 * |
No | 110 (71) | 24.65 (15.61) |
Nonmotor Symptoms | n (%) | Mean (SD) | Mean Difference | 95% CI | p | |
---|---|---|---|---|---|---|
Esophageal dysmotility | Yes | 21 (14.2) | 37.5 (15.23) | 11.78 | 4.79, 18.76 | 0.001 * |
No | 127 (85.8) | 25.72 (15.71) | ||||
Apathy/depression | Yes | 78 (49.0) | 34.8 (15.22) | 14.37 | 9.77, 18.97 | 0.001 * |
No | 79 (51.0) | 20.42 (13.76) | ||||
Insomnia | Yes | 64 (41.3) | 33.47 (16.77) | 10.22 | 5.26, 15.18 | 0.001 * |
No | 91 (58.7) | 23.25 (14.33) | ||||
Dysphagia | Yes | 55 (35.5) | 33.1 (15.00) | 8.73 | 3.54, 13.91 | 0.001 * |
No | 100 (64.5) | 24.37 (15.98) | ||||
Pain | Yes | 90 (58.1) | 33.2 (15.08) | 13.66 | 8.93, 18.39 | 0.001 * |
No | 65 (41.9) | 19.54 (14.17) | ||||
Urinary incontinence | Yes | 79 (51.0) | 32.7 (15.46) | 10.68 | 5.83, 15.53 | 0.001 * |
No | 76 (49.0) | 22.02 (15.09) | ||||
Fatigue | Yes | 104 (67.1) | 32.46 (15.01) | 15.16 | 10.25, 20.06 | 0.001 * |
No | 51 (32.9) | 17.30 (13.47) | ||||
Delayed gastric emptying | Yes | 43 (27.7) | 31.79 (16.37) | 5.98 | 0.32, 11.64 | 0.038 * |
No | 112 (72.3) | 25.81 (15.82) | ||||
Constipation | Yes | 75 (48.4) | 31.12 (14.72) | 7.06 | 2.04, 12.08 | 0.006 * |
No | 80 (51.6) | 24.05 (16.75) | ||||
Daytime sleepiness | Yes | 85 (54.8) | 31.09 (15.87) | 8.01 | 2.99, 13.00 | 0.002 * |
No | 70 (45.2) | 23.08 (15.48) |
Stage 3, 4, 5 % (n) | Stage 1, 2 % (n) | (χ2) | p | OR | 95% CI | |||
---|---|---|---|---|---|---|---|---|
Slowness of movement | Yes | 35.04 (48) | 64.96 (89) | 2.431 | 0.118 | 2.69 | 0.74 | 9.78 |
No | 5.88 (3) | 14.42 (15) | ||||||
Tremor | Yes | 34.57 (28) | 65.43 (53) | 0.213 | 0.644 | 1.17 | 0.59 | 2.29 |
No | 31.08 (23) | 68.92 (51) | ||||||
Postural instability | Yes | 45.83 (44) | 54.17 (52) | 19.099 | 0.001 * | 6.28 | 2.59 | 15.23 |
No | 11.86 (7) | 88.14 (52) | ||||||
Difficulty turning | Yes | 59.15 (42) | 40.85 (29) | 40.896 | 0.001 * | 12.06 | 5.22 | 27.89 |
No | 10.71 (9) | 89.29 (75) | ||||||
Dyskinesias | Yes | 57.78 (26) | 42.22 (19) | 17.771 | 0.001 * | 4.65 | 2.21 | 9.75 |
No | 22.73 (25) | 11.27 (85) | ||||||
Relationship between NMS and the recoded HY stages | ||||||||
Fatigue | Yes | 42 (40.38) | 62 (59.62) | 8.013 | 0.004 * | 3.16 | 1.39 | 7.17 |
No | 9 (17.65) | 42 (82.35) | ||||||
Pain | Yes | 39 (43.33) | 51 (56.67) | 10.575 | 0.001 * | 3.37 | 1.59 | 7.16 |
No | 12 (18.46) | 53 (81.54) | ||||||
Daytime sleepiness | Yes | 36 (42.35) | 49 (57.65) | 7.61 | 0.005 * | 2.69 | 1.31 | 5.5 |
No | 15 (21.43) | 55 (78.57) | ||||||
Apathy/depression | Yes | 31 (40.79) | 45 (59.21) | 4.2 | 0.04 * | 2.03 | 1.02 | 4.02 |
No | 20 (25.32) | 59 (74.68) | ||||||
Urinary incontinence | Yes | 35 (44.3) | 44 (55.7) | 9.48 | 0.002 * | 2.98 | 1.46 | 6.05 |
No | 16 (21.05) | 60 (78.95) | ||||||
Constipation | Yes | 34 (45.33) | 41 (54.67) | 10.16 | 0.001 * | 3.07 | 1.52 | 8.2 |
No | 17 (21.25) | 63 (78.75) | ||||||
Dysphagia | Yes | 25 (45.45) | 30 (54.55) | 6.08 | 0.013 * | 2.37 | 1.18 | 4.74 |
No | 26 (26) | 74 (74) | ||||||
Insomnia | Yes | 31 (48.44) | 33 (51.56) | 11.91 | 0.001 * | 3.33 | 1.66 | 6.69 |
No | 20 (21.98) | 71 (78,02) | ||||||
Delayed gastric emptying | Yes | 18 (41.86) | 25 (58.14) | 2.16 | 0.141 | 1.73 | 0.83 | 3.57 |
No | 33 (29.46) | 79 (70.54) | ||||||
Esophageal dysmotility | Yes | 12 (52.17) | 11 (47.83) | 4.54 | 0.033 * | 2.6 | 1.05 | 6.39 |
No | 39 (29.55) | 93 (70.45) |
DBS Treatment | Mean (SD) | Mean Difference | 95% CI | p | |
---|---|---|---|---|---|
Total PDQ-39 SI | Yes | 31.98 (14.78) | 5.67 | −0.60, 11.96 | 0.076 |
No | 26.3 (16.33) | ||||
Total mobility | Yes | 49.21 (30.42) | 16.55 | 4.98, 28.12 | 0.005 * |
No | 32.66 (29.28) | ||||
Total AVD | Yes | 42.44 (27.68) | 13.11 | 2.41, 23.8 | 0.017 * |
No | 29.33 (27.18) | ||||
Total emotional well-being | Yes | 39.58 (24.11) | 4.21 | −5.21, 13.64 | 0.378 |
No | 35.36 (24.03) | ||||
Total stigma | Yes | 20.31 (24.78) | 1.35 | −8.29, 11.01 | 0.781 |
No | 18.95 (25.07) | ||||
Total social support | Yes | 19.53 (18.64) | 1.3 | −5.98, 8.59 | 0.724 |
No | 18.22 (18.58) | ||||
Total cognitive status | Yes | 29.29 (18.97) | 0.28 | −8.21, 8.27 | 0.995 |
No | 29.26 (21.53) | ||||
Total communication | Yes | 26.56 (22.24) | 13.21 | 5.64, 20.78 | 0.001 * |
No | 13.34 (18.5) | ||||
Total pain | Yes | 28.9 (21.48) | −4.35 | −13.38, 4.67 | 0.342 |
No | 33.26 (23.41) |
Factors | PDQ-39 SI Mean (SD) | Mean Difference | 95% CI | p | |
---|---|---|---|---|---|
Number of medicines | ≥4 | 33.68 (16.9) | 10.58 | 15.52, 5.64 | 0.001 * |
<4 | 23.10 (14.12) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Candel-Parra, E.; Córcoles-Jiménez, M.P.; Delicado-Useros, V.; Hernández-Martínez, A.; Molina-Alarcón, M. Relationship between Motor and Nonmotor Symptoms and Quality of Life in Patients with Parkinson’s Disease. Nurs. Rep. 2022, 12, 1-12. https://doi.org/10.3390/nursrep12010001
Candel-Parra E, Córcoles-Jiménez MP, Delicado-Useros V, Hernández-Martínez A, Molina-Alarcón M. Relationship between Motor and Nonmotor Symptoms and Quality of Life in Patients with Parkinson’s Disease. Nursing Reports. 2022; 12(1):1-12. https://doi.org/10.3390/nursrep12010001
Chicago/Turabian StyleCandel-Parra, Eduardo, María Pilar Córcoles-Jiménez, Victoria Delicado-Useros, Antonio Hernández-Martínez, and Milagros Molina-Alarcón. 2022. "Relationship between Motor and Nonmotor Symptoms and Quality of Life in Patients with Parkinson’s Disease" Nursing Reports 12, no. 1: 1-12. https://doi.org/10.3390/nursrep12010001